CN1463977A - Process for extracting amygdalin and use thereof - Google Patents
Process for extracting amygdalin and use thereof Download PDFInfo
- Publication number
- CN1463977A CN1463977A CN 02134201 CN02134201A CN1463977A CN 1463977 A CN1463977 A CN 1463977A CN 02134201 CN02134201 CN 02134201 CN 02134201 A CN02134201 A CN 02134201A CN 1463977 A CN1463977 A CN 1463977A
- Authority
- CN
- China
- Prior art keywords
- peach kernel
- reaction source
- add
- redistillation
- glycosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses the extraction and the application of amygdalin as organic compound extracted from almond and other seed kernel of rosaceous plant. Amygdalin may be used in medicine for preventing and treating migraine, hypertension, chronic inflammation, and other reaction source diseases.
Description
Technical field
The present invention relates to a kind of bitter peach kernel glycosides of organic chemistry composition (Amygdalin, VitaminB that extracts by peach kernel
17, claim Vitamin B17 again) extracting method and application thereof, the particularly application in the medicine of reaction source kinds diseases such as preparation prevention and treatment migraine, essential hypertension.
Background technology
Disease occurred frequently such as migraine, essential hypertension is a present world medicine class disease of the clear and definite cause of disease not as yet, can not etiological treatment, can only relief of symptoms and can not cure, and may recur at any time, even threat to life.From medical history, symptom, (reaction source place local subcutaneous is injected low dose of PROCAINE HCL, PHARMA GRADE or lignocaine for sign and clinical trial treatment, soup only can soak into the skin and the subcutis of 2-3 cm diameter, the local anaesthetics permeates cell membranes, the gate of the sodium-ion channel of side blocking-up within it, make the cell at reaction source place can not produce action potential and conduction of impulse, injected about 2 minutes, symptom such as blood pressure or pain can take a turn for the better, disappearance along with local anesthetic action, symptom and sign recovers again, and the pernicious stimulation of unusual bioenergy of reaction source is described, causes the symptom and sign of reaction source kinds disease to recover again) the middle discovery, the body local tissue is by physics, chemistry or the biological cytogene damage that causes, can make cytometaplasia, formation can discharge unusual bioelectricity, bio signals such as hertzian wave, and become primary focus, this unusual bio signal can be directly or the pernicious stimulation target tissue in reflectivity ground, produce pathologic reaction, and secondary disease takes place, this pernicious stimulus, just be called the injury response source, be called for short reaction source.Cause the reaction source that a certain disease takes place, be called relevant reaction source, otherwise claim irrelevant reaction source.The disease that reaction source causes is called the reactinogenicity disease.For example, the migraine that reaction source causes claims the reactinogenicity migraine; The hypertension that reaction source causes claims reactinogenicity hypertension, promptly present alleged essential hypertension or essential hypertension.The big class reactinogenicity disease that reaction source causes claims the reaction source kinds disease.In the clinical reaction source kinds disease of having found migraine, essential hypertension, chronic bronchitis, chronic anaphylaxis inflammation, irregular pulse, coronary heart disease, ankylosing spondylitis are arranged, the dizzy pain of back limb muscle arthrodynia, chronic gastritis, chronic colitis and cerebral concussion etc.This numerous reaction source kinds disease is that intensity, frequency and four parameters of target tissue of the unusual bio signal that discharged by the different sites of reaction source, reaction source are determined.According to the principle of reaction source, reaction source kinds diseases such as essential hypertension, migraine are checked, treated and prevent, be called the reaction source therapy and (draw certainly: Liu Jisheng, Liao Jianxian.The clinical observation of reaction source therapy for treating essential hypertension.The hypertension magazine.1995，3(3)：218～220)。The reaction source therapy is to treat in approach such as reaction source place local subcutaneous liquid medicine injection (subcutaneous have high amount of drug can the fastest the most direct healing reaction source) or quiet, oral pharmaceutical, and with control or eliminate reaction source, symptom and sign just obtains taking a turn for the better or recovery from illness.
Known peach kernel has anti-inflammatory, anticoagulation, antithrombotic formation, antianaphylaxis, slightly expands the effect of blood vessel, microcirculation improvement, and the nutrition supply at reaction source place is increased, and promotes the abnormal function of cell to transfer normal function to.Bitter peach kernel glycosides can effectively be treated diseases such as schistosomal cirrhosis, posthepatitic cirrhosis, and anti-mutation, the antitumor (VB of human body safe treatment amount are arranged
17Have or not certain antitumor action, remain at present in more difference.As 3-6gVB every day that is grown up
17Powder adds in the G/W quiet, and treatment advanced esophageal cancer, lung cancer, tumour are not seen obviously and dwindled, but can more obviously improve symptoms such as cancer pain and hydrothorax) effect.Become human oral VB
17Powder 4g every day continues two weeks, or quiet administration one month, and visible toxic reaction, also can show as ECG T wave and change for see more with Digestive tract, and the room is early won, and after the drug withdrawal, above toxic reaction all can disappear.If dosage is kept to 0.6-1.2g every day, then can avoid toxic reaction (drawing) from " China's book on Chinese herbal medicine " 4 96 pages.We screen two over thousands of kinds of medicines, and in the produce effects compound, preferred again and clinical verification finds that the bitter peach kernel glycosides of Semen Persicae extract has significant curative effect in reaction source kinds diseases such as treatment migraine, essential hypertension.This composition can not only be protected Normocellular 26S Proteasome Structure and Function, and anomalous structure that can also the repair cell gene is closed abnormal function, destroys and eliminates the extra high cell of grade malignancy that can not repair, so cell on the throne only has normal function.This is because the structures shape function.Thereby reaction source discharges the defunctionalization of pernicious unusual bio signal and cures and transfer healthy tissues to, and the reaction source kinds disease of original secondary did not recur along with healing yet.Cure relevant reaction source at premorbid, but just prophylactic response source class disease.
Summary of the invention
The purpose of this invention is to provide a kind of extract and application thereof of peach kernel of disease such as reaction source kinds such as thoroughly healing and prevention of migraine, essential hypertension etc.The bitter peach kernel glycosides of indication of the present invention is to be extracted by peach kernel to form, and gets peach kernel 16g, extracts and makes the 100ml injection liquid.Peach kernel contains bitter peach kernel glycosides and is about 3.6%, and it is peach kernel 300g that the every 2ml of this injection liquid contains the prescription that bitter peach kernel glycosides is about the 11.52mg. long-acting sustained-release agent, extracts the 26ml concentrated solution.Manufacture process:
Former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 16g → adding pure water 600ml → distillation 40min → get distillate 300ml in the insoluble container in water-bath, redistillation 15min → get concentrated solution 100ml, add lignocaine 200mg, make every 1ml contain lignocaine 2mg (intravenous administration need not add) → adding sodium bicarbonate, regulate pH value to 7 → filtration → embedding, 2ml/ props up (soup achromatism and clarity) → sterilization → shady and cool lucifuge place and preserves.
The making method of long-acting sustained-release agent: former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 300g → adding pure water 1500ml → distillation 80min → get distillate 1000ml in the insoluble container in water-bath, redistillation 40min → get distillate 300ml, redistillation 30min → get distilled and concentrated solution 26ml is made into finished product behind the carrier of adding long-acting sustained-release agent and selective aggregation reaction source.
Usage and dosage: subcutaneous injection once a day, each 2-40ml
Intravenous drip once a day, each 30ml.
Bitter peach kernel glycosides provided by the invention is reaction source kinds such as healing and prevention of migraine, essential hypertension disease thoroughly, no longer recurrence after curing fully.And in the safe treatment weight range, be applied to clinical, non-evident effect, only the subcutaneous injection part has and swells and ache, but hot compress take a turn for the better, lump does not disappear can treat with reaction source then fade away.This reaction only appears at the reaction source place, and can play the ocular effect of favourable landmark identification reaction source.Not finding has detrimentally affect to hepatic and renal function.
Embodiment
Embodiment one: former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 16g → adding pure water 600ml → distillation 40min → get distillate 300ml in the insoluble container in water-bath, redistillation 15min → get concentrated solution 100ml, add lignocaine 200mg, make every 1ml contain lignocaine 2mg → adding sodium bicarbonate, regulate pH value to 7 → filtration → embedding, 2ml/ props up (soup achromatism and clarity) → sterilization → shady and cool lucifuge place and preserves.
Usage and dosage: subcutaneous injection once a day, each 2ml.
Embodiment two: former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 16g → adding pure water 600ml → distillation 40min → get distillate 300ml redistillation 15min → get concentrated solution 100ml in the insoluble container in water-bath, add lignocaine 200mg, make every 1ml contain lignocaine 2mg → adding sodium bicarbonate, regulate pH value to 7 → filtration → embedding, 2ml/ props up (soup achromatism and clarity) → sterilization → shady and cool lucifuge place and preserves.
Usage and dosage: subcutaneous injection once a day, each 40ml.
Embodiment three: former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 16g → adding pure water 600ml → distillation 40min → get distillate 300ml in the insoluble container in water-bath, redistillation 15min → get concentrated solution 100ml → adding sodium bicarbonate, regulate pH value to 7 → filtration → embedding, 2ml/ props up (soup achromatism and clarity) → sterilization → shady and cool lucifuge place and preserves.
Usage and dosage: intravenous drip once a day, each 30ml.
Embodiment four: former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 300g → adding pure water 1500ml → distillation 80min → get distillate 1000ml in the insoluble container in water-bath, redistillation 40min → get distillate 300ml, redistillation 30min → get distilled and concentrated solution 26ml is made into finished product behind the carrier of adding long-acting sustained-release agent and selective aggregation reaction source.
Claims (3)
1. bitter peach kernel glycosides (Amygdalin, claim Vitamin B17 again) extracting method, it is characterized in that: former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 16g → adding pure water 600ml → distillation 40min → get distillate 300ml in the insoluble container in water-bath, redistillation 15min → get concentrated solution 100ml, add lignocaine 200mg, make every 1ml contain lignocaine 2mg (intravenous administration need not add) → adding sodium bicarbonate, regulate pH value to 7 → filtration → embedding, 2ml/ props up (soup achromatism and clarity) → sterilization → shady and cool lucifuge place and preserves.
2. the long-acting sustained-release agent extracting method of a bitter peach kernel glycosides (Amygdalin), it is characterized in that: former medicine peach kernel powder be broken into as sesame big → add peach kernel flour 300g → adding pure water 1500ml → distillation 80min → get distillate 1000ml in the insoluble container in water-bath, redistillation 40min → get distillate 300ml, redistillation 30min → get distilled and concentrated solution 26ml is made into finished product behind the carrier of adding long-acting sustained-release agent and selective aggregation reaction source.
3. the purposes of a bitter peach kernel glycosides is characterized in that: the application of this composition in the medicine of reaction source kinds diseases such as preparation prevention and treatment migraine, essential hypertension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021342016A CN100420698C (en) | 2002-06-18 | 2002-06-18 | Process for extracting amygdalin and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021342016A CN100420698C (en) | 2002-06-18 | 2002-06-18 | Process for extracting amygdalin and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1463977A true CN1463977A (en) | 2003-12-31 |
| CN100420698C CN100420698C (en) | 2008-09-24 |
Family
ID=29744147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021342016A Expired - Fee Related CN100420698C (en) | 2002-06-18 | 2002-06-18 | Process for extracting amygdalin and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100420698C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4841560B2 (en) * | 2004-11-29 | 2011-12-21 | ユニベルシタート ポリテクニカ デ カタルーニャ | Use of an amygdalin analog for the treatment of psoriasis |
-
2002
- 2002-06-18 CN CNB021342016A patent/CN100420698C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4841560B2 (en) * | 2004-11-29 | 2011-12-21 | ユニベルシタート ポリテクニカ デ カタルーニャ | Use of an amygdalin analog for the treatment of psoriasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100420698C (en) | 2008-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102895460B (en) | Traditional Chinese medicine composition for fracture and soft tissue injury | |
| CN101091769A (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN103768531A (en) | Traditional Chinese medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
| CN100420698C (en) | Process for extracting amygdalin and use thereof | |
| CN102078472A (en) | Medicament for treating verruca wart | |
| CN104706919B (en) | A kind of pharmaceutical composition for the treatment of ulcer in body surface | |
| CN100460004C (en) | Medicated wine for treating cancer and tumor and method for preparing same | |
| CN102641480B (en) | Traditional Chinese medicine composite used for treating microcirculation disturbance and preparation method thereof | |
| CN105687444A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method and application thereof | |
| CN101152223A (en) | Use of poplar leaf phenols extract in treating cardiovascular disease and extracting method thereof | |
| CN102293845B (en) | Gu yan kang | |
| CN104288395A (en) | Black plaster for treating rheumatoid arthritis and preparation method of black plaster | |
| CN101474329B (en) | Moschus skin recovery paste for treating damaged skin | |
| CN103735676B (en) | A kind of compound Chinese medicinal preparation for the treatment of traumatic injury and its preparation method and application | |
| CN109646558A (en) | A kind of Chinese patent drug and preparation method thereof for treating lung cancer | |
| CN102125607A (en) | Medicinal composition and preparation method thereof | |
| CN1259949C (en) | Capsule for treating wound | |
| CN1387883A (en) | Chinese medicine extract and its application | |
| CN105998908A (en) | Chinese herba preparation for treating tumors and resisting toxic and side effects of chemotherapy and preparation method thereof | |
| CN105079202A (en) | Pien Tze Huang hemorrhoids ointment and preparation method thereof | |
| CN1827140A (en) | Chinese medicinal pill for treating cancer | |
| CN104606578A (en) | Traditional Chinese medicine composition for treating superficial thrombophebitis caused by medicine | |
| CN104352812A (en) | Black plaster for curing rheumatic arthritis and preparation method thereof | |
| CN1637010A (en) | Extraction and application of paeonol amygdaloside | |
| CN113975382A (en) | Blood stasis removing pill and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Liu Jisheng Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Liu Jisheng Document name: Notification of Termination of Patent Right |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080924 Termination date: 20110618 |